Guggenheim lifts Heron Therapeutics Inc [HRTX] price estimate. Who else is bullish?

- Advertisements -

Heron Therapeutics Inc [NASDAQ: HRTX] stock went on an upward path that rose over 19.27% on Monday, amounting to a one-week price increase of more than 138.18%. The company report on November 14, 2023 at 4:05 PM that Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance.

Heron is increasing full-year 2023 Net Product Sales guidance for the oncology care franchise to a range of $104 million to $106 million from a prior range of $99 million to $103 million.

- Advertisements -

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


We anticipate full-year 2023 Net Product Sales to be in the range of $123 million to $125 million and full-year 2024 Net Product Sales to be in the range of $138 million to $158 million.

Over the last 12 months, HRTX stock dropped by -55.63%. The one-year Heron Therapeutics Inc stock forecast points to a potential upside of 76.87. The average equity rating for HRTX stock is currently 1.00, trading closer to a bullish pattern in the stock market.

- Advertisements -

The market cap for the stock reached $195.09 million, with 150.07 million shares outstanding and 147.77 million shares in the current float. Compared to the average trading volume of 2.48M shares, HRTX stock reached a trading volume of 10704271 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Heron Therapeutics Inc [HRTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HRTX shares is $5.62 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HRTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Heron Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2020.

- Advertisements -

The Average True Range (ATR) for Heron Therapeutics Inc is set at 0.13, with the Price to Sales ratio for HRTX stock in the period of the last 12 months amounting to 1.59.

HRTX Stock Performance Analysis:

Heron Therapeutics Inc [HRTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 138.18. With this latest performance, HRTX shares gained by 113.18% in over the last four-week period, additionally sinking by -10.34% over the last 6 months – not to mention a drop of -55.63% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HRTX stock in for the last two-week period is set at 74.00, with the RSI for the last a single of trading hit 81.86, and the three-weeks RSI is set at 67.03 for Heron Therapeutics Inc [HRTX]. The present Moving Average for the last 50 days of trading for this stock 0.8635, while it was recorded at 0.9414 for the last single week of trading, and 1.5937 for the last 200 days.

Insight into Heron Therapeutics Inc Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Heron Therapeutics Inc [HRTX] shares currently have an operating margin of -157.20 and a Gross Margin at +49.04. Heron Therapeutics Inc’s Net Margin is presently recorded at -169.05.

Return on Total Capital for HRTX is now -82.95, given the latest momentum, and Return on Invested Capital for the company is -90.33. Return on Equity for this stock declined to -399.43, with Return on Assets sitting at -65.40. When it comes to the capital structure of this company, Heron Therapeutics Inc [HRTX] has a Total Debt to Total Equity ratio set at 1,160.31. Additionally, HRTX Total Debt to Total Capital is recorded at 92.07, with Total Debt to Total Assets ending up at 62.75. Long-Term Debt to Equity for the company is recorded at 1,140.46, with the Long-Term Debt to Total Capital now at 90.49.

Reflecting on the efficiency of the workforce at the company, Heron Therapeutics Inc [HRTX] managed to generate an average of -$896,670 per employee. Receivables Turnover for the company is 2.46 with a Total Asset Turnover recorded at a value of 0.39.Heron Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.91 and a Current Ratio set at 2.43.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HRTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Heron Therapeutics Inc go to 47.50%.

Heron Therapeutics Inc [HRTX] Institutonal Ownership Details

The top three institutional holders of HRTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in HRTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in HRTX stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *